[ Price : $8.95]
A CDER guidance recommends against using DBP and DEHP as excipients in drug and biologic products.[ Price : $8.95]
FDA denies a Teva petition seeking limitations on approving generic forms of Copaxone without comment on specific requirements it ...[ Price : $8.95]
CDER medical reviewers say they believe that Zogenix Zohydro ER may be more subject to abuse than combination hydrocodone products...[ Price : $8.95]
Chelsea Therapeutics International reports positive preliminary results for Study 306B, a Phase 3 trial evaluating Northera for tr...[ Price : $8.95]
CDRH releases its six strategic priorities for 2013.[ Price : $8.95]
FDA and AstraZeneca reach agreement on label changes for Faslodex injection that updates results from the companys CONFIRM trial i...[ Price : $8.95]
An FDA report discusses the 35 new molecular entities the agency approved in FY 2012.[ Price : $8.95]
Lawyers from Skadden and Foley Hoag examine the future of FDA and Justice Department enforcement actions in the wake of this weeks...